We also know that some of the most important medical breakthroughs often result from collaborative R&D agreements and from partnerships. To find potential new therapies for patients we look both inside and outside AbbVie for promising discoveries. We partner and collaborate with peer companies, universities, non-governmental organisations, as well as other relevant groups, to help find solutions for patients around the globe—because we recognise there are times when we can accomplish more together than alone.
Our Passion Helps Patients
Innovation is the cornerstone of AbbVie’s business as a global biopharmaceutical company. Our focus is on developing medicines that can offer strong clinical performance and, provide measurable patient benefit—particularly in areas where there is significant need—such as hepatitis C, neuroscience, immunology, oncology, chronic kidney disease and gynecology.
AbbVie’s approach to scientific innovation builds on an impressive track record of developing breakthrough science. Our scientists discovered and developed two of the first medications to treat HIV infection, helping to change the outlook for many patients impacted by this disease. Our work in immunology has benefited patients with rheumatoid arthritis, psoriasis, Crohn’s disease and other chronic, autoimmune conditions. We continue to advance scientific research across many disease areas.
